Acute eprosartan-induced intrarenal vasodilation in hypertensive humans is not influenced by dietary sodium intake or angiotensin II co-infusion

Journal of Hypertension

Volumn 34, Issue 8, 2016, Pages 1607-1614

  Van Twist, Daan J L ^a   Houben, Alfons J H M ^a   De Leeuw, Peter W ^a,b   Kroon, Abraham A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

Author keywords

angiotensin receptor blocker; AT 1 R; eprosartan; hypertension; kidney; renin angiotensin system; sodium

Indexed keywords

ANGIOTENSIN II; EPROSARTAN; SODIUM; XENON 133; ACRYLIC ACID DERIVATIVE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; SODIUM INTAKE; THIOPHENE DERIVATIVE;

ADULT; ARTICLE; DIAGNOSTIC IMAGING; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; KIDNEY ANGIOGRAPHY; KIDNEY BLOOD FLOW; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SODIUM INTAKE; SODIUM RESTRICTION; SODIUM URINE LEVEL; VASODILATATION; ADMINISTRATION AND DOSAGE; AGED; DRUG EFFECTS; HYPERTENSION; KIDNEY ARTERY; KIDNEY CIRCULATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHARMACOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINE;

ACRYLATES; ADULT; AGED; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; RECEPTOR, ANGIOTENSIN, TYPE 1; RENAL ARTERY; RENAL CIRCULATION; RENIN-ANGIOTENSIN SYSTEM; SODIUM; SODIUM, DIETARY; THIOPHENES; VASODILATION;

EID: 84969753081     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000974     Document Type: Article

References (30)

1. Fenoy FJ, Milicic I, Smith RD, Wong PC, Timmermans PB, Roman R. Effects of DuP 753 on renal function of normotensive and spontaneously hypertensive rats. Am J Hypertens 1991; 4 (4 Pt 2):321S-326S.
2. Bovee KC, Wong PC, Timmermans PB, Thoolen MJ. Effects of the nonpeptide angiotensin II receptor antagonist DuP 753 on blood pressure and renal functions in spontaneously hypertensive PH dogs. Am J Hypertens 1991; 4 (4 Pt 2):327S-333S.
3. Price DA, De?Oliveira JM, Fisher ND, Hollenberg NK. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension 1997; 30 (2 Pt 1):240-246.
4. Wuerzner G, Burnier M. Effects of selective angiotensin II and beta(1)-receptor blockade on renal haemodynamics, and sodium handling during orthostatic stress in healthy individuals. J Hypertens 2006; 24:S89-S93.
5. Paterna S, Parrinello G, Scaglione R, Costa R, Bova A, Palumbo VA, et al. Effect of long-Term losartan administration on renal haemodynamics and function in hypertensive patients. Cardiovasc Drugs Ther 2000; 14:529-532.
6. Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens Suppl 1994; 12:S37-S42.
7. Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, Brouard R, et al. Short-Term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995; 25 (4 Pt 1):602-609.
8. Gandhi SK, Ryder DH, Brown NJ. Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans. Hypertension 1996; 28:961-966.
9. Burnier M, Rutschmann B, Nussberger J, Versaggi J, Shahinfar S, Waeber B, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993; 22:339-347.
10. Delles C, Klingbeil AU, Schneider MP, Handrock R, Weidinger G, Schmieder RE. Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. Am J Hypertens 2003; 16:1030-1035.
11. Delles C, Jacobi J, John S, Fleischmann I, Schmieder RE. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Kidney Int 2002; 61:1462-1468.
12. van Twist DJ, Houben AJ, de Haan MW, Mostard GJ, Kroon AA, de Leeuw PW. Angiotensin-(1-7)-induced renal vasodilation in hypertensive humans is attenuated by low sodium intake and angiotensin II co-infusion. Hypertension 2013; 62:789-793.
13. Ruan X, Wagner C, Chatziantoniou C, Kurtz A, Arendshorst WJ. Regulation of angiotensin II receptor AT1 subtypes in renal afferent arterioles during chronic changes in sodium diet. J Clin Invest 1997; 99:1072-1081.
14. Wierema TK, Houben AJ, Kroon AA, Koster D, van der Zander K, van Engelshoven JM, et al. Nitric oxide dependence of renal blood flow in patients with renal artery stenosis. JAmSoc Nephrol 2001; 12:1836-1843.
15. Dielis AW, Smid M, Spronk HM, Houben AJ, Hamulyak K, Kroon AA, et al. Changes in fibrinolytic activity after angiotensin II receptor blockade in therapy-resistant hypertensive patients. J Thromb Haemost: JTH 2007; 5:1509-1515.
16. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-612.
17. Deinum J, Derkx FH, Schalekamp MA. Improved immunoradiometric assay for plasma renin. Clin Chem 1999; 45 (6 Pt 1):847-854.
18. Kesteloot H, Joossens JV. The relationship between dietary intake and urinary excretion of sodium, potassium, calcium and magnesium: Belgian Interuniversity Research on Nutrition and Health. J Hum Hypertens 1990; 4:527-533.
19. Peng Y, Knox FG. Comparison of systemic and direct intrarenal angiotensin II blockade on sodium excretion in rats. Am J Physiol 1995; 269 (1 Pt 2):F40-F46.
20. Brown IJ, Tzoulaki I, Candeias V, Elliott P. Salt intakes around the world: implications for public health. Int J Epidemiol 2009; 38:791-813.
21. Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH. Hypertension: renin-Angiotensin-Aldosterone system alterations. Circ Res 2015; 116:960-975.
22. Ingert C, Grima M, Coquard C, Barthelmebs M, Imbs JL. Effects of dietary salt changes on renal renin-Angiotensin system in rats. Am J Physiol Renal Physiol 2002; 283:F995-F1002.
23. Navar LG. Intrarenal renin-Angiotensin system in regulation of glomerular function. Curr Opin Nephrol Hypertens 2014; 23:38-45.
24. Singh RR, Lankadeva YR, Denton KM, Moritz KM. Improvement in renal hemodynamics following combined angiotensin II infusion and AT1R blockade in aged female sheep following fetal unilateral nephrectomy. PLoS One 2013; 8:e68036.
25. van Twist DJ, Kroon AA, de Leeuw PW Angiotensin-(1-7) As A Strategy in the Treatment of Hypertension? Curr Opin Nephrol Hypertens 2014; 23:480-486
26. Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008; 68:1207-1225.
27. Balt JC, Mathy MJ, Pfaffendorf M, van Zwieten PA. Sympatho-inhibitory properties of various AT1 receptor antagonists. J Hypertens Suppl 2002; 20:S3-S11.
28. Ohlstein EH, Brooks DP, Feuerstein GZ, Ruffolo Jr. R.R. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997; 55:244-251.
29. Dendorfer A, Dominiak P, Tempel K, Raasch W Peripheral sympatholytic actions of four AT1 antagonists: Are they relevant for long-Term antihypertensive efficacy? J Hypertens 2005; 23:1861-1867
30. Michel MC, Foster C, Brunner HR, Liu L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 2013; 65:809-848.